Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Clinical Study of Evaluating the Efficacy and Safety of CM326 in Subjects With Moderate to Severe Asthma

Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Understand the study and voluntarily sign the informed consent form.

• Age ≥18 and ≤80 years old, male or female, weight ≥40 kg.

• The subject has been diagnosed with asthma for at least 1 year.

• Pre-bronchodilator FEV1 measured ≤80% of the normal predicted value.

• A positive bronchodilation test within 24 months before informed consent or at screening.

• The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LAMA, LTRA, Oral corticosteroids, theophylline, for at least 3 months before signing the informed consent, and maintained stable treatment regimen and dosage for at least 1 month before signing the informed consent.

• Asthma Control Questionnaire-5 (ACQ-6) score ≥1.5.

• Subjects must have experienced at least one severe asthma exacerbation event within 12 months before informed consent, and have not experienced a severe asthma exacerbation event within 30 days before informed consent.

• ≥ 80% compliance with usual asthma controller therapy in subjects during the screening phase

⁃ Voluntarily use highly effective contraception from the time of signing the informed consent form until 3 months after the last dose.

Locations
Other Locations
China
Ruijin Hospital, Shanghai Jiao tong University School of Medicine
RECRUITING
Shanghai
Contact Information
Primary
Clinical Trials Information Group officer
ctr-contact@cspc.cn
031169085587
Time Frame
Start Date: 2026-01-23
Estimated Completion Date: 2029-03-31
Participants
Target number of participants: 230
Treatments
Experimental: CM326
CM326 subcutaneous (SC)
Placebo_comparator: Placebo
placebo, subcutaneous (SC)
Related Therapeutic Areas
Sponsors
Leads: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials